

## Parkinsonism

CCFP Priority Topics

### Presentation

- TRAP - any 2 of Tremor, Rigidity, Akinesia/bradykinesia, Postural instability

#### • Parkinson's Disease

- Clinical Diagnosis
- Cardinal S&S: Distal Resting Tremor (3-6Hz, pill-rolling); Rigidity; Bradykinesia; Asymmetrical onset
- Additional S&S: Difficulty turning over in bed, opening jars, rising from a chair; Poor heel-to-toe gait; Shuffling gait; Loss of balance; Micrographia; Loss of olfaction
- Therapeutic Challenge; adequate response to levodopa trial

### Differential Diagnosis

- **Symptoms Suggesting Alternate Diagnosis:** Lack of Levodopa response, hallucinations, prominent/early dementia, early postural instability, severe & early autonomic dysfunction, upward gaze paralysis, involuntary mvmts (other than tremor)

	History	S&S	Levodopa Response	Imaging	Comments
<b>Drug-Induced Parkinsonism</b>	Causative Drug, eg antipsychotic, metoclopramide	Tremor, rigidity, bradykinesia Bilateral symptoms		N	May persist up to 1yr after drug discontinuation
<b>Vascular Parkinsonism</b>	Stepwise progression CVA, TIA; comorbid CVD	Fixed deficits from prev events		White Matter Lesions +/- BG	Common; Cerebrovascular dz is ++ prevalent
<b>Essential Tremor</b>	FHx - multiple members Minimal progression	Tremor - action-based, bilateral, lessens w ETOH; No EPS; No levodopa response	None	N dopaminergic system (SPECT)	Common
<b>Normal Pressure Hydrocephalus</b>	Ataxia, Dementia, Urinary Incontinence	Ataxic gait; Mental status change		Hydrocephalus	Distinct clinical features
<b>Progressive Supranuclear Palsy</b>	Onset >40y/o; Frequent falls	Vertical gaze paralysis (dec vertical saccades); ++ postural instability; Resting tremor; Nuchal dystonia; N olfaction		Brainstem atrophy (MRI)	
<b>Multiple System Atrophy</b>	Autonomic & urinary dysfunction; Parkinsonism w poor levodopa response; Cerebellar dysfunction	Resting tremor; Mild olfactory impairment	Transient Response (25%)	Findings of degeneration (MRI)	Eg: Shy Drager syndrome, olivopontocerebellar atrophy, nigrostriatal degeneration Dec sphincter EMG; urodynamic changes; altered CV responses
<b>Corticobasal Degeneration</b>	Cortical & cognitive impairment w involuntary mvmts	Apraxia; Aphasia; Sensory d/o's; Positive Babinski; Asymmetrical parkinsonism; Myoclonus; Dystonia		Asymmetric atrophy of frontal/parietal areas (MRI) Dec glucose metabolism (PET)	Heterogeneous presentation; Commonly underdiagnosed
<b>Dementia with Lewy Bodies</b>	Cognitive impairment; Hallucinations; Delirium episodes; Parkinsonism	Attention & visuospatial abilities - impaired; inc falls; syncopal episodes		Dec glucose metabolism (PET)	++ Intolerance to neuroleptic drugs

N - normal; BG - basal ganglia; SPECT - single photon emission CT; Source: Shobha SR et al. Parkinson's Disease: Diagnosis and Treatment. *Am Fam Physician*. 2006 Dec 15;74(12):2046-2054

### Investigations

- Physical Examination of Tremor
  - Resting Tremor - seen w hand resting in lap
  - Need to distinguish from Kinetic Tremor (occurs w mvmts) & Postural Tremor (limb is held against gravity)
  - LOOK: Observe (1) Hands in lap/arms at sides, (2) Extend arms to do finger-to-nose test, (3) Perform tasks (drink from glass, write/draw)
    - Classify: Involved body part (arms, head), When tremor present (rest, intention), Frequency (fast/slow), Amplitude (fine/coarse)
    - (4) Stand & Walk - difficulty initiating mvmt, dec arm swing, shuffling gate
  - FEEL/MOVE: Rigidity & Bradykinesia - flex/ext arms, cogwheeling?

## Parkinsonism

CCFP Priority Topics

	Occurrence	Examples
<b>Rest Tremor</b>	Dec w target-directed mvmt; Limb supported against gravity; Muscles not activated	PD; Drug-induced Parkinsonism (neuroleptics, metoclopramide)
<b>Action Tremor</b>	Any voluntary muscle contraction	
<b>Postural</b>	Inc w voluntary mvmt; Limb maintains position against gravity; Extending arms in front of body	Physiologic Tremor; Essential Tremor; Metabolic disturbance; Drug/ETOH withdrawal
<b>Kinetic - Simple - Intention</b>	Not change w target-directed mvmt; Mvmt of extremities - supination/pronation, flex/ext Inc w target-directed mvmt; Visually guided mvmt - eg finger-to-nose testing	--- Cerebellar Lesion (stroke, MS, tumour); drug-induced (Li, ETOH)
<b>Isometric</b>	Muscle contraction against stationary objects	Holding a heavy object in hand
<b>Task-Specific</b>	Occurs w specific action	Handwriting tremor; Musician's tremor.

Source: Smaga S. Tremor. *Am Fam Physician*. 2003 Oct 15;68(8):1545-1552.

- CT or MRI - if diagnosis of idiopathic PD is uncertain and other diagnoses are being considered

### Management

- Goal: maximize prnt autonomy & QOL; Initiate therapy at onset of functional impairment
- **United Parkinson's Disease Rating Scale (UPDRS)** - standardized assessment tool; Measures (1) mental effects, (2) ADL limitations, (3) motor impairment, (4) treatment/disease complications (see below).
- Assessing Functional Status

Non-Motor Symptoms	
Symptom	Management Strategies
<b>Cognitive Impairment *COMMON*</b>	R/O medical etiology (infection, metabolic d/o, dehydration); Occurs in 20-40% of PD prnts; Dec or D/C anticholinergics, DOPA agonists, MAO-B inhibitor, NMDA receptor inhibitor; Rx: cholinesterase inhibitor
<b>Constipation</b>	Inc fluid & fiber intake; Inc PA; D/C anticholinergics; Use bowel protocol PRN
<b>Depression *COMMON*</b>	Counselling; Meds - SSRIs, TCAs (w caution due to s/e)
<b>Dysphagia</b>	Swallowing assessment by OT; Inc "On" time, ie time of dec symptoms, & tell prnts to eat during this time; soft foods; ? gastrostomy
<b>Orthostatic Hypotension</b>	D/C antiHTN meds; Elevate HOB; Get up slowly; Consider fludrocortisone or midodrine
<b>Psychosis, Hallucinations, or Delirium *COMMON*</b>	Usually drug induced .: dec or D/C anticholinergics, DOPA agonists, MAO-B inhibitor, NMDA receptor inhibitor; Severe hallucinations - onsider low-dose clozapine (monitor CBC for agranulocytosis) or quetiapine
<b>Sleep Disturbance</b> Daytime Somnolence Nighttime Awakenings REM Sleep Behaviour D/O	• D/C DOPA agonists • Due to bradykinesia; Consider qhs dose of sustained-release Levodopa or an adjuvant (COMT-I, DOPA agonist) • Dec or D/C qhs dose of anti-PD drugs; Consider clonazepam
<b>Urinary Urgency</b>	Dec qhs fluid intake; Consider tolterodine or oxybutynin; Urology referral

R/O rule out: d/o disorder; D/C discontinue; PA physical activity  
Source: Shobha SR et al. Parkinson's Disease: Diagnosis and Treatment. *Am Fam Physician*. 2006 Dec 15;74(12):2046-2054

# Parkinsonism

CCFP Priority Topics

<b>Early-Stage Treatment</b> (PD duration <5y; no motor complications from levodopa)			
	<b>Adverse Effects (AEs)</b>	<b>Indications</b>	<b>Comments</b>
<b>Anticholinergics</b> Benzotropine ( <i>Cogentin</i> ) Trihexyphenidyl ( <i>Artane</i> )	Dry mouth & eyes; constipation; hypotension; cognitive impairment; urinary retention	Symptomatic Control (mild - moderate benefit) Ptnts <70y/o w disabling resting tremor & N cognition	More AEs than other drugs (GI, neuropsych) Low effectiveness
<b>Carbidopa/Levodopa</b> Immediate Sustained-Release ( <i>Sinemet</i> )	Nausea - more likely at <70-100g/d Somnolence; Dyskinesia; Hypotension; Hallucinations	<b>**Primary tx for symptomatic PD**</b> Older ptnts w severe motor s's	Most effective. Less effect on speech, posture, gait. Combined w carbidopa to prevent peripheral conversion of levodopa to dopamine.
<b>MAO-B Inhibitors</b> Selegiline ( <i>Eldepryl</i> ) Rasagaline ( <i>Azilect</i> )	DI w other MAO inhibitors S - nausea, insomnia R - wt loss, hypotension, dry mouth	Symptomatic Control (mild - moderate benefit); Adjuvant therapy for motor fluctuations	
<b>NMDA Receptor Inhibitor</b> Amantadine ( <i>Symmetrel</i> )	Nausea; Hypotension; Hallucinations; Confusion; Edema	Akinesia, rigidity, tremor, dyskinesia	

<b>Late-Stage Treatment</b> (Ptnts on Carbi/Levodopa w motor complications, >5y of treatment)			
<b>Motor Complications</b>	<b>Medications</b>	<b>Surgery</b>	
<ul style="list-style-type: none"> <li>Occurs in ~40% of ptnts after 5yrs of treatment</li> <li><b>Dyskinesia</b> - involuntary stereotyped mvmts of head, trunk, limbs, occ resp muscles</li> <li><b>"Wearing-Off" Effect</b> - therapeutic effects of Levodopa wear off sooner .: Parkinsonism s's reappear; ie <b>"On/Off Effect"</b></li> </ul>	<ul style="list-style-type: none"> <li>Treat resurgence of motor complications by adding (1) DOPA agonist, (2) MAO-B inhibitor, (3) COMT inhibitor</li> </ul>	<ul style="list-style-type: none"> <li>Deep Brain Stimulation - subthalamic nucleus</li> <li>Inc motor function</li> <li>Dec motor fluctuations, dyskinesia, antiPD meds</li> </ul>	
	<b>Adverse Effects (AEs)</b>	<b>Indications</b>	<b>Comments</b>
<b>COMT Inhibitors</b> Entacapone ( <i>Comtan</i> ) Tolcapone ( <i>Tasmar</i> )	Diarrhea; inc Levodopa AEs E - bright orange urine R - liver failure (rare; monitor LFTs)	Treats "wearing-off" effect (motor fluctuations) of Levodopa.	Dec Levo metabolism, .: inc 1/2 life May need to dec Levodopa dose if inc dyskinesia.
<b>Dopamine Agonists</b> Bromocriptine ( <i>Parlodel</i> ) Pergolide ( <i>Permax</i> )  Pramipexole ( <i>Miramax</i> ) Ropinirole ( <i>Requip</i> )	Nausea, Hallucinations, Dyskinesias B - h/a, dizziness Per - somnolence, hallucinations, edema, fibrosis of lung/cardiac/retroperitoneum Pr, R - somnolence, edema, hallucinations, hypotension	May be early tx in ptnts w mild disease at younger ages. B - Early & advanced disease Per - Initial; Adjunct therapy to levodopa  Pr, R - Early; motor fluctuations	

Source: Shobha SR et al. Parkinson's Disease: Diagnosis and Treatment. *Am Fam Physician*. 2006 Dec 15;74(12):2046-2054

<b>Allied Health Resources</b>					
<b>Occupational Therapy</b>	<b>Physical Therapy</b>	<b>Speech Therapy</b>	<b>Nutritional Support</b>	<b>Counseling</b>	<b>Parkinson Society Canada</b>
<ul style="list-style-type: none"> <li>Improved ADL performance</li> </ul>	<ul style="list-style-type: none"> <li>Exercises - stretching, strengthening, balance training</li> <li>Improved gait, balance, ADL performance</li> </ul>	<ul style="list-style-type: none"> <li>Voice training</li> <li>Improved voice &amp; speech</li> </ul>	<ul style="list-style-type: none"> <li>High-fiber diet - dec constipation</li> <li>PRO restriction - for ptnts w dec Levodopa response b/c amino acids interfere</li> </ul>	<ul style="list-style-type: none"> <li>Support for ptnt, partner &amp; family</li> </ul>	<ul style="list-style-type: none"> <li>Support &amp; ptnt education</li> <li>Improved QOL</li> </ul>

## Resources

- American Family Physician
  - Tremor (<http://www.aafp.org/afp/2003/1015/p1545.html>)
  - Parkinson's Disease: Diagnosis & Treatment (<http://www.aafp.org/afp/2006/1215/p2046.html>)
- Unified Parkinson's Disease Rating Scale (UPDRS)